ClinicalTrials.gg

Program

ecnoglutide

Also written as “XW003 injection”, “ecnoglutide tablets” and “Ecnoglutide Injection”.

Its studies are mostly in Obesity · Sleep Apnea, Obstructive · Diabetes Mellitus, Type 2 · Osteoarthritis, Knee, led by 2 companies.

Furthest: phase 3, since Dec 25, 202213 company-led studies, 7 open or runningNext primary completion: Jan 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hangzhou Sciwind Biosciences127 open or runningphase 3since Dec 25, 2022Dec 25, 2022Jan 5, 2027phase 2 · NCT07243171
Sciwind Biosciences APAC CO Pty.10 open or runningphase 2since Oct 17, 2021Oct 17, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2021First study: phase 2 study in ObesityNew to Sciwind Biosciences APAC CO Pty.Sciwind Biosciences APAC CO Pty. · NCT05111912 · 206 enrolled · Australia
  2. Dec 25, 2022Hangzhou Sciwind Biosciences's first studies: 2 phase 3 studies in Diabetes Mellitus, Type 2New to Hangzhou Sciwind BiosciencesHangzhou Sciwind Biosciences · NCT05680155, NCT05680129
  3. Mar 20, 2023Phase 3 study in OverweightHangzhou Sciwind Biosciences · NCT05813795 · 664 enrolled · China
  4. Jul 29, 2023Phase 1 study in Healthy VolunteersHangzhou Sciwind Biosciences · NCT06335134 · 57 enrolled · China
  5. Jul 9, 2025Phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07073417 · 163 enrolled · China
  6. Aug 13, 2025Phase 1 study in ObesityHangzhou Sciwind Biosciences · NCT07143227 · 48 enrolled · China
  7. Nov 17, 2025Phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07243171 · 126 planned · China
  8. Jan 28, 20262 phase 3 studies in Sleep Apnea, ObstructiveHangzhou Sciwind Biosciences · NCT07434050, NCT07387094
  9. Jul 21, 2026Phase 3 study in Osteoarthritis, KneeHangzhou Sciwind Biosciences · NCT07734311 · 360 planned · China
  10. Sep 14, 2026Phase 3 study in ObesityHangzhou Sciwind Biosciences · NCT07836270 · 192 planned · China
  11. Oct 28, 2026Phase 2 study in OverweightHangzhou Sciwind Biosciences · NCT07929298 · 180 planned · China

Ahead

  1. Jan 5, 2027Primary completion: phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07243171
  2. Feb 27, 2027Primary completion: phase 2 study in ObesityHangzhou Sciwind Biosciences · NCT07073417
  3. Sep 3, 2027Primary completion: phase 2 study in OverweightHangzhou Sciwind Biosciences · NCT07929298
  4. Dec 16, 2027Primary completion: phase 3 study in Sleep Apnea, ObstructiveHangzhou Sciwind Biosciences · NCT07387094

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07929298Overweight · China2Not yet recruitingHangzhou Sciwind BiosciencesSep 3, 2027180
NCT07836270Obesity · China3Not yet recruitingHangzhou Sciwind BiosciencesJun 8, 2028192
NCT07734311Osteoarthritis, Knee · China3RecruitingHangzhou Sciwind BiosciencesMay 31, 2028360
NCT07434050Sleep Apnea, Obstructive · China3RecruitingHangzhou Sciwind BiosciencesJun 19, 2028140
NCT07387094Sleep Apnea, Obstructive · China3RecruitingHangzhou Sciwind BiosciencesDec 16, 2027140
NCT07243171Obesity · China2RecruitingHangzhou Sciwind BiosciencesJan 5, 2027126
NCT07143227Obesity · China1CompletedHangzhou Sciwind BiosciencesApr 18, 202648
NCT07073417Obesity · China2Active, not recruitingHangzhou Sciwind BiosciencesFeb 27, 2027163
NCT06335134Healthy Volunteers · China1CompletedHangzhou Sciwind BiosciencesJan 8, 202457
NCT05813795Overweight · China3CompletedHangzhou Sciwind BiosciencesJun 20, 2024664
NCT05680155Diabetes Mellitus, Type 2 · China3CompletedHangzhou Sciwind BiosciencesJun 12, 2024211
NCT05680129Diabetes Mellitus, Type 2 · China3CompletedHangzhou Sciwind BiosciencesJul 3, 2024623
NCT05111912Obesity · Australia2CompletedSciwind Biosciences APAC CO Pty.Nov 16, 2022206

How it is read

Names in the registry

  • “XW003 injection”, 5 entries
  • “ecnoglutide tablets”, 2 entries
  • “Ecnoglutide Injection”, 2 entries
  • “ecnoglutide tablet”, 1 entry
  • “Ecnoglutide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.